Ecallantide: Its pharmacology, pharmacokinetics, clinical efficacy and tolerability

Expert Review of Clinical Immunology

Volumn 6, Issue 1, 2010, Pages 29-39

  Bernstein, Jonathan A ^a   Qazi, Momina ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute attacks; Anaphylaxis; Ecallantide efficacy; Hereditary angioedema; Immunogenicity; Kallikrein; Pichia pastoris; Safety; Subcutaneous

Indexed keywords

ECALLANTIDE; KALBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CLOTTING DISORDER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECONOMIC ASPECT; EDEMA; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPOXIA; IMMUNOGENICITY; INCIDENCE; INJECTION SITE REACTION; LEUKOCYTOSIS; LIVER DYSFUNCTION; NAUSEA; NEPHROTOXICITY; PATHOGENESIS; PICHIA PASTORIS; POSTMARKETING SURVEILLANCE; PSYCHOLOGICAL ASPECT; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SOCIAL ASPECT; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; VOMITING;

ANGIOEDEMAS, HEREDITARY; ANIMALS; HUMANS; KALLIKREINS; PATIENT SELECTION; PEPTIDES; RECOMBINANT PROTEINS; RISK ASSESSMENT; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME;

EID: 77649090208     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.60     Document Type: Review

References (25)

1. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 120, 416-422 (2007).
2. Lehmann A. Ecallantide (Dyax/Genzyme). Curr. Opin. Investig. Drugs 7, 282-290 (2006).
3. Bernstein JA. Hereditary angioedema: A current state-of-the-art review, VIII: Current status of emerging therapies. Ann. Allergy Asthma Immunol. 100, S41-S46 (2008).
4. Zuraw BL. Hereditary angiodema: A current state-of-the-art review, IV: Short- and long-term treatment of hereditary angioedema: out with the old and in with the new? Ann. Allergy Asthma Immunol. 100, S13-S18 (2008).
5. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol. Med. 15, 69-78 (2009).
6. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J. Allergy Clin. Immunol. 119, 1497-1503 (2007).
7. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin. Investig. Drugs 15, 1077-1090 (2006).
8. Gompels MM, Lock RJ. C1 inhibitor deficiency: Diagnosis. Clin. Exp. Dermatol. 30, 460-462 (2005).
9. Gompels MM, Lock RJ, Abinun M et al. C1 inhibitor deficiency: Consensus document. Clin. Exp. Immunol. 139, 379-394 (2005).
10. Davis AE 3rd. The pathophysiology of hereditary angioedema. Clin. Immunol. 114, 3-9 (2005).
11. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697 (1998).
12. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J. Allergy Clin. Immunol. 104, 1321-1322 (1999).
13. Wilson D, Rentz A, Zuraw B et al. Economic costs associated with acute and chronic management of hereditary angioedema [abstract]. Ann. Allergy Asthma Immunol. 102, P250 (2009).
14. Zuraw BL. Current and future therapy for hereditary angioedema. Clin. Immunol. 114, 10-16 (2005).
15. Epstein TG, Bernstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs 68, 2561-2573 (2008).
16. Codispote C, Rezvani M, Bernstein J. Successful use of C1 inhibitor during mitral valve replacement surgery with cardiopulmonary bypass. Ann. Allergy Asthma Immunol. 101, 220 (2008).
17. Jaffe CJ, Atkinson JP, Gelfand JA, Frank MM. Hereditary angioedema: The use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery. J. Allergy Clin. Immunol. 55, 386-393 (1975).
18. Prematta M, Gibbs JG, Pratt EL, Stoughton TR, Craig TJ. Fresh frozen plasma for the treatment of hereditary angioedema. Ann. Allergy Asthma Immunol. 98, 383-388 (2007).
19. Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: A current state-of-the-art review, V: Attenuated androgens for the treatment of hereditary angioedema. Ann. Allergy Asthma. Immunol. 100, S19-S22 (2008).
20. Williams A, Baird LG. DX-88 and HAE: A developmental perspective. Transfus. Apher. Sci. 29, 255-258 (2003).
21. Vernon M, Rentz A, Wyrwich K, White M, Grienenberger A. Psychometric validation of 2 patient-reported outcome (PRO) measures to assess symptom severity and changes in symptoms in hereditary angioedema (HAE). Qual. Life. Res. (2009) (In press).
22. Caballero T, Lopez-Serrano C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol. 117, 476-477; discussion 477 (2006).
23. First-ever study conducted demonstrating economic, individual, and societal burden of hereditary angioedema (news release) (2008) http://investor.dyax.com/phoenix. zhtml?c=122200&p=irol-newsArticle&ID= 1224235&highlight=ecallantide
24. Advisory Committee Briefing Document. Kalbitor® (ecallantide) for acute attacks of hereditary angioedema (BLA 125277) (2009) http://google2.fda. gov/search?output=xml-no-dtd&lr=&proxystylesheet=FDA&client= FDA&site=FDA&getfields=&q=+briefing+document+on+ecallantide+2009
25. Pulmonary Allergy Drugs Advisory Committee Briefing Document: Kalbitor® (ecallantide) for acute attacks of hereditary angioedema (BLA 125277) (2009) www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Pulmonary-AllergyDrugsAdvisoryCommittee/ucm126203.htm